NEW YORK, Nov. 6, 2017 /PRNewswire-USNewswire/ -- Lupus Research Alliance welcomes compelling new data, presentedat the American College of Rheumatology (ACR) annual meeting that demonstrated significant benefit for lupus patients treated with StelaraŽ (ustekinumab), a prescription medicine from the Janssen Pharmaceutical Companies. StelaraŽ is not approved for
Based on the positive results from the Phase 2 study, Janssen announced plans to test StelaraŽ in a future Phase 3 program. Phase 3 trials involve larger groups of patients and are necessary for the FDA to consider evaluating additional efficacy and safety data in order to consider potential approval of a drug as a treatment for a disease such as lupus.
"Lupus is a devastating autoimmune disease with symptoms that can range from debilitating fatigue to life-threatening organ damage," noted Kenneth M. Farber, President and CEO of the Lupus Research Alliance. "These positive Phase 2 results and the initiation of Phase 3 development bring the hope of a new treatment closer to a community in urgent need of more options. The Lupus Research Alliance is particularly excited about the promise of StelaraŽ, having recognized its potential in lupus early on."
In 2013 two of the Lupus Research Alliance legacy organizations, the Alliance for Lupus Research (ALR) and Lupus Research Institute (LRI), initiated an ongoing drug repurposing program to determine potential lupus treatments among drugs already approved by the FDA for other conditions. The ALR & LRI commissioned Drs. Peter Lipsky and Amrie Grammer of AMPEL BioSolutions LLC to carry out an in-depth analysis of all drugs & biologics approved for human use in the United States. After a comprehensive review of more than 150 therapeutics, AMPEL compiled a list of potential lupus treatments (LRxL), in consultation with researchers and members of the lupus community, which was then vetted by an expert committee; StelaraŽ was the top-scoring biologic. Based on this work, the Lupus Research Alliance encouraged Janssen to test StelaraŽ in lupus, and the company subsequently opened a Phase 2 global trial in 2015.
"The availability of a new treatment with a favorable safety profile would represent an important and welcome advance for patients who have seen only one new treatment in over 50 years," commented Mary Crow, MD, Co-Chair of the Lupus Research Alliance Scientific Advisory Board as well as Physician-in-Chief and Chair of the Department of Medicine at Hospital for Special Surgery and Chief of the Division of Rheumatology at HSS and NewYork-Presbyterian/Weill Cornell Medical Center. "Having advocated for Janssen to explore StelaraŽ in lupus, we are encouraged by these promising results and strongly support the company's plans to further test StelaraŽ in Phase 3 studies."
About LupusLupus is a chronic, complex autoimmune disease that affects millions of people worldwide. More than 90% of lupus sufferers are women, mostly young women between the ages of 15 to 44. Women of color are especially at risk. In lupus, the immune system, which is designed to protect against infection, creates antibodies that attack the body's own tissues and organs -- the kidneys, brain, heart, lungs, blood, skin, and joints.
About the Lupus Research AllianceThe Lupus Research Alliance leads the quest to free the world from lupus through the power of science. The 501 (c)(3) is the only international private funder devoted to lupus research. The organization propels lupus research in new directions to pursue better treatments while driving to a cure. Because the Lupus Research Alliance Board of Directors funds all administrative and fundraising costs, 100% of all donations goes to support lupus research programs. And with pivotal discoveries, the Lupus Research Alliance is breaking through.
StelaraŽ is a registered trademark of Janssen Biotech, Inc.
View original content:http://www.prnewswire.com/news-releases/lupus-research-alliance-prompted-stelara-study-for-lupus--results-show-potential-for-new-treatment-option-300549968.html
SOURCE Lupus Research Alliance
Subscribe to our Free Newsletters!
Cholestatic jaundice occurs when the flow of bile (chole) between the liver and small intestine is ...
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...View All